--- title: "Wolverine Stack: Research Bench | BodyHackGuide" url: https://www.bodyhackguide.co/stack/wolverine-stack description: "the Wolverine Stack is a community nickname for BPC-157 combined with TB-500, a pairing no controlled human study has tested. No dosing. Research use only." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Research bench · research use only # Wolverine Stack BPC-157 with TB-500, plus the GHK-Cu and KPV that turn the pair into GLOW and KLOW no dosing on this page human data on 2 of 4 no human study has timed the pair; a rat test scored tendons at four weeks, and two uncontrolled reports checked patients after one to about twelve months advanced ## 01 Overview the Wolverine Stack is a community nickname for BPC-157 combined with TB-500, a pairing no controlled human study has tested. GLOW is BPC-157, TB-500 and GHK-Cu, and KLOW is those three plus KPV. the Wolverine Stack bench sets each peptide's record beside the pair's and gives no amount, schedule or route for any of them. ### 02 Read this first every product on the Wolverine Stack bench is research use only, and each BHG Labs listing says it is not for human or veterinary use. nothing here is an amount, a schedule or a route, and the bench does not say how often anything is injected. BHG Labs sells BPC-157 and TB-500 together as one 10 mg vial whose listing gives the total, not the split between the two, and KLOW as an 80 mg vial whose listing names no components. a certificate, where BHG Labs posts one on its certificates page (bhglabs.co/coa), covers a sample from one lot. three hard stops apply. both halves of the pair are prohibited in tested sport. BPC-157 and the thymosin beta-4 sequence that TB-500 copies drive new vessel growth in lab work, and neither BPC-157 nor TB-500 has a carcinogenicity study. GLOW and KLOW add copper, the metal that Wilson disease treatment works to remove. FDA moved these peptides out of Category 2 in April 2026 because their nominators withdrew, and that is not an approval. ## 03 The bench: 4 compounds roles and evidence, not amounts. this page does not publish doses or schedules for research compounds. evidence ladder human data on 2 of 4 - 2 small human trials - 1 lab and animal only - 1 no human data 01 BPC-157small human reports, abstract-only trials the guide (https://www.bodyhackguide.co/compound/bpc-157) the half of the pair with the healing reputation: FDA's July 2026 briefing quotes a clinic website that says BPC-157 has been called the 'wolverine compound' for its 'intense healing properties'. a synthetic 15-residue peptide, GEPPPGKPADDAGLV, described as a partial sequence of a protein found in human gastric juice. FDA states that its molecular targets have not been identified. evidence: mostly rats, mostly one laboratory: 174 of the 228 PubMed records that name BPC-157 in the title or abstract list Predrag Sikiric of the University of Zagreb as an author (search run 21 October 2026). his group reported faster healing of cut Achilles tendons in rats, and a group in Taiwan found BPC-157 sped the migration of rat tendon fibroblasts and raised vessel growth in chick membrane, rat hind limb and human endothelial cell models. in people, the randomized studies exist only as meeting abstracts: an enema safety study in 32 healthy volunteers (2002 and 2003) and a two-week enema trial in 53 patients with ulcerative colitis (2005), whose data FDA judged inadequate to support efficacy. three uncontrolled reports led by the same first author at Florida clinics add 30 people: 16 knee-pain patients surveyed by phone, 12 women with interstitial cystitis and 2 adults given intravenous infusions. a 2026 systematic review rated all three poor quality, with very low certainty. a September 2026 report of three dental nerve-injury patients gave BPC-157 alongside TB-500, ARA-290, dexamethasone and bupivacaine. watch for: FDA found no carcinogenicity study and no human pharmacokinetic data outside two enema studies, where BPC-157 was not detected in plasma. in 28-day injection studies in rats and dogs, FDA notes clotting-time changes and a raised liver enzyme (ALT). FDA's adverse event search through 4 December 2025 returned three reports, all for injected BPC-157. a woman also using a compounded thymosin had redness and swelling at the injection site. a man went to an emergency room short of breath. a woman using a research-labeled product that also held TB500 had darkened skin and gums. FDA placed BPC-157 in Category 2, its group of substances nominated for 503A compounding that may present significant safety risks, on 29 September 2023. on 22 April 2026 FDA moved it, with 11 other peptides, to a table of withdrawn nominations, which is neither an approval nor Category 1. FDA staff recommended against listing BPC-157 in May 2026. news reports say FDA's advisory committee voted for listing at its 23 July 2026 meeting. FDA has posted no minutes or vote results; the vote is advice, and FDA had not acted on it by 21 October 2026. WADA names BPC-157 under S0, prohibited at all times. 02 TB-500no human data on its own the guide (https://www.bodyhackguide.co/compound/tb-500) the half of the pair credited with cell movement: a synthetic, N-acetylated seven-residue peptide, Ac-LKKTETQ, copying residues 17 to 23 of thymosin beta-4. thymosin beta-4 is a 43-residue peptide regarded as the main G-actin sequestering peptide in mammalian tissue, and those seven residues hold its actin-binding site. a Hong Kong racing laboratory described TB-500 in 2012 as a veterinary preparation and built a doping test for it in horses. evidence: for TB-500 itself, FDA's May 2026 review found no human data by any route and no animal study of the acetylated peptide healing a wound. the non-acetylated fragment matched full-length thymosin beta-4 in repairing skin wounds in aged mice in a 2003 study, and FDA notes that acetylation alters a peptide's charge, size and binding, so those results cannot be directly carried over to TB-500. in a 2024 cell study TB-500 did not speed the closure of fibroblast scratch wounds beyond vehicle, while one of its breakdown products, Ac-LKKTE, did. a July 2026 rat study, published after FDA's review, found a significant gain in the load repaired Achilles tendons could bear at four weeks in the arm its authors call TB-500. the published human trials of thymosin beta-4 used the full-length peptide. on the eye: a 9-patient severe dry eye trial, a 72-person dry eye trial that missed both primary endpoints, and an 18-patient neurotrophic keratopathy trial whose four-week complete-healing comparison missed significance. on the skin: venous and pressure ulcer trials. by vein: a safety study in 40 healthy volunteers that found no dose-limiting toxicity. watch for: the label does not fix the molecule: a French horse-racing laboratory found that products sold as TB500 and TB1000 did not consistently match their stated contents, and the 2026 rat study's authors equate TB-500 with synthetic thymosin beta-4. FDA's concern for injected TB-500 is a possible immune reaction, which aggregation and peptide impurities could amplify, and FDA found no carcinogenicity or reproductive study. TB-500 followed BPC-157's compounding path: Category 2 on 29 September 2023, the withdrawn table on 22 April 2026, an FDA staff recommendation against listing, and, according to news reports, a committee vote for listing in July 2026. FDA has posted no minutes or vote results; the vote is advice, and FDA had not acted on it by 21 October 2026. WADA's 2026 list names thymosin beta-4 and its derivatives, TB-500 among them, under S2.3, prohibited at all times. the one ClinicalTrials.gov record that names TB-500, NCT07487363, calls itself a fictional study written as an example. 03 GHK-Cusmall topical human trials only the guide (https://www.bodyhackguide.co/compound/ghk-cu) what GLOW adds to the pair, and what KLOW keeps: the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide isolated from human plasma. in fibroblast culture GHK-Cu raised collagen synthesis from picomolar concentrations, peaking at 1 nanomolar. evidence: the wound and skin trials are topical and disagree. a gel beat vehicle on diabetic plantar ulcers in a multicenter randomized trial, with median closure of 98.5 percent against 60.8 percent. a 0.4 percent cream did no better than placebo on venous ulcers in 86 evaluable patients, while silver sulfadiazine did. after CO2 laser resurfacing, 13 completers improved with or without GHK-Cu products, and only their own satisfaction ratings favored GHK-Cu. a 2026 review also reports an 18-participant split-face eyebrow study with positive hair results that did not define which GHK-Cu species was applied. FDA describes the human data for injectable GHK-Cu as limited, and a 2026 review calls the clinical record sparse. no published study in any species has given GHK-Cu with BPC-157, TB-500 or KPV (PubMed searches, 21 October 2026). watch for: FDA lists injectable GHK-Cu among the withdrawn nominations, citing a possible immune reaction from aggregation and peptide impurities. GHK-Cu for other routes went back into Category 1 in May 2026, and FDA says it intends to consult its advisory committee on listing GHK-Cu before the end of February 2027. a 2026 review found that published delivery studies seldom measure how much of the copper is bound or free. Wilson disease is copper overload, and its treatment lowers copper, partly with zinc salts that block copper uptake in the gut; GHK-Cu adds copper, and no study has given it to anyone with a copper disorder. whether GHK-Cu's copper oxidizes the other peptides in a shared vial is untested; copper ions with hydrogen peroxide do oxidize glucagon in the region where it binds copper. 04 KPVanimal and cell only the guide (https://www.bodyhackguide.co/compound/kpv) what KLOW adds on top of GLOW: lysine-proline-valine, residues 11 to 13 of alpha-MSH. in rodent tissue and cell tests KPV did not displace alpha-MSH binding, and FDA's review says the melanocortin receptors are unlikely to be its targets. evidence: cell and rodent work only. at nanomolar concentrations KPV inhibited NF-kB and MAP kinase signaling in human intestinal and T cell lines after entering through the PepT1 transporter, and added to drinking water it reduced DSS and TNBS colitis in mice. a group in Muenster found KPV helped mice recover from DSS colitis and T-cell transfer colitis, partly independent of the MC1 receptor. FDA's May 2026 review found no human exposure data by any route, no case reports and no adverse event reports. watch for: KPV crossed human cadaver skin poorly in a lab study FDA cites. in mice, KPV packed into nanoparticles inside a colon-targeted gel matched the effect of free KPV at a concentration 12,000 times lower, and the low-dose result needed a carrier that a plain vial does not have. FDA found no reproductive study, and its staff recommended against listing KPV for compounding. according to news reports, FDA's advisory committee voted for listing in July 2026. FDA has posted no minutes or vote results; the vote is advice, and FDA had not acted on it by 21 October 2026. KPV's Category 2 dates match the pair's: in on 29 September 2023, out to the withdrawn table on 22 April 2026. WADA's 2026 list does not name KPV, and its S0 class also covers unapproved substances it does not name, so that is not a clearance. ## 04 At a glance form lyophilized vials, as sold; BPC-157 also as dry-fill units in a sealed bottle human data no controlled human study of BPC-157 with TB-500; seven patients in two uncontrolled reports got BPC-157 with a thymosin beta-4 product, three of them as TB-500 alongside ARA-290, dexamethasone and bupivacaine; for BPC-157, three uncontrolled reports in 30 people, 4 of whom also got thymosin beta-4, and two randomized enema studies known only as meeting abstracts; none for TB-500 on its own; small topical trials for GHK-Cu; none for KPV evidence 2 small human trials, 1 lab and animal only, 1 no human data BHG Labs listings 5 products, below level advanced timeline no human study has timed the pair; a rat test scored tendons at four weeks, and two uncontrolled reports checked patients after one to about twelve months schedule not applicable: the bench gives no schedule, and no controlled human study has tested one for the pair ### 05 Why these together the claim is that the two pull different repair levers. BPC-157 is credited with vessels and tendon cells: it raised vessel density in chick membrane and rat limb models, with VEGFR2 activation, and made rat tendon fibroblasts migrate faster. TB-500 is credited with cell movement through actin: the seven-residue motif it copies is the actin-binding site of thymosin beta-4, and in culture that motif alone matched the whole peptide in moving human endothelial cells and sprouting chick vessels. the one direct test, 32 rats with repaired Achilles tendons in four groups of eight, found the TB-500 arm's tendons significantly stronger than controls at four weeks and the combination no better than either peptide alone. the authors suggest the two may converge on shared downstream pathways. in people the pair appears only inside uncontrolled clinic reports: 4 knee-pain patients given BPC-157 with a thymosin beta-4 product of unstated form, and 3 dental nerve-injury patients given BPC-157 and TB-500 together with ARA-290, dexamethasone and bupivacaine. GLOW adds GHK-Cu, KLOW adds GHK-Cu and KPV, and no study has tested either addition with the pair. ### 06 Overlap the two levers overlap more than the pitch suggests. both peptides drive new vessels in lab work, BPC-157 with VEGFR2 activation and thymosin beta-4 through its actin motif. both touch actin and cell movement: BPC-157 raised F-actin and FAK and paxillin activation in cultured rat tendon fibroblasts and made them migrate faster, and thymosin beta-4 holds unpolymerized G-actin. the clearest difference is how well each is defined: thymosin beta-4 has a known binding partner in actin, while FDA states that BPC-157's molecular targets have not been identified. the overlap is literal at the product level: the BPC-157 + TB-500 vial names both peptides and GLOW and KLOW carry both by market name, so any two of those three overlap on both peptides. ### 07 Conflicts tested sport: WADA's 2026 list prohibits BPC-157 under S0 and thymosin beta-4 and its derivatives, TB-500 by name, under S2.3, at all times. WADA does not name KPV or GHK-Cu, but its S0 class prohibits at all times any substance with no current approval for human therapeutic use; whether S0 covers either one is a reading of that wording, not a WADA listing. cancer history: BPC-157 and the actin motif of thymosin beta-4 both drive new vessel growth in lab work, FDA found no carcinogenicity study of BPC-157 or TB-500, and FDA calls the human safety risks of TB-500 unknown. blood thinners and liver: FDA's summary of 28-day BPC-157 injection studies reports a shortened clotting test (aPTT) in rats, a prolonged one in dogs and raised ALT, a liver enzyme, and no study has tested BPC-157 in people taking anticoagulants. Wilson disease or another copper disorder with GLOW or KLOW: GHK-Cu supplies copper, zinc salts treat Wilson disease by competing with copper for absorption, and nobody has tested GHK-Cu in a copper disorder. pregnancy: FDA found no reproductive study of TB-500 or KPV, and for BPC-157 one rat study found no birth defects without a full reproductive program. overlapping products: the BPC-157 + TB-500 vial names both peptides, GLOW and KLOW carry both by market name, and neither the combined listing nor the KLOW listing states how much of each peptide a vial holds. immune reactions: FDA lists a possible immune response as a risk of compounded BPC-157, TB-500 and injectable GHK-Cu, citing aggregation or peptide impurities. ### 08 What the evidence actually is BPC-157 with TB-500: one controlled study, 32 rats with repaired Achilles tendons, in which the pair did no better than either peptide alone at four weeks, and two uncontrolled human reports covering seven patients. BPC-157: mostly rat work, with 174 of 228 PubMed records listing Predrag Sikiric of Zagreb as an author. BPC-157 in people: three uncontrolled reports that a 2026 systematic review rated very low certainty, and two randomized enema studies known only as meeting abstracts, the ulcerative colitis one judged inadequate by FDA. TB-500: no human data on its own in FDA's May 2026 review, a 2024 cell study in which TB-500 did no better than vehicle on fibroblast scratch wounds, and one 2026 rat tendon study. the published human trials of thymosin beta-4 used the full-length peptide, as eye drops, on skin ulcers and in one intravenous safety study. GHK-Cu: three topical wound and skin-resurfacing trials, one positive and two that failed on objective measures, and no published study with BPC-157, TB-500 or KPV. KPV: cell and mouse work, with no human exposure data by any route. FDA's adverse event file holds one report for a research-labeled BPC-157 and TB-500 product: skin and gum darkening after a week of use that returned on rechallenge. FDA judged the skin and gum darkening likely due to the BPC-157 and TB-500 product but could not assign it to either peptide. ### 09 What people report the promise in peptide marketing is faster recovery from musculoskeletal injury, and a 2026 scoping review of six compounds sold as peptide supplements, BPC-157, TB-500 and GHK-Cu among them, found that promise unsubstantiated by human trials. for BPC-157 and TB-500 the reports of use in people are clinic case series and FDA adverse event records. for the pair, seven patients in two uncontrolled clinic reports got BPC-157 with a thymosin beta-4 product, and six were reported improved. FDA's adverse event file holds one report of skin and gum darkening after a research-labeled BPC-157 and TB-500 product. ### Who It's For people who searched for the Wolverine Stack, or for BPC-157 with TB-500, and want each peptide's record and the pair's before reading about GLOW or KLOW ### What to Track any local reaction, darkening of skin or gums, breathlessness, and for each vial the lot number and whether a certificate for that lot exists and gives an amount for each peptide ## 10 Sourced at BHG Labs BHG Labs posts certificates at bhglabs.co/coa. Research use only. Code BHG20 takes 20% off at checkout, and the store links below apply it for you. BPC-157 + TB-500 10mg $74.99 https://bhglabs.co/product/bpc-157-tb-500-10mg/?ref=zmgqyxku&coupon=BHG20 KLOW 80mg $119.99 https://bhglabs.co/product/klow-80mg/?ref=zmgqyxku&coupon=BHG20 GHK-Cu 50mg $49.99 https://bhglabs.co/product/ghk-cu-50mg/?ref=zmgqyxku&coupon=BHG20 KPV 10mg $54.99 https://bhglabs.co/product/kpv-10mg/?ref=zmgqyxku&coupon=BHG20 BPC-157 500mcg, 60 Dry-Fill Units $69.99 https://bhglabs.co/product/bpc-157-500mcg-60-dry-fill-units/?ref=zmgqyxku&coupon=BHG20 BHG Labs has no GLOW listing and names TB-500 only on the BPC-157 + TB-500 vial. ### Read the compound guides BPC-157: https://www.bodyhackguide.co/compound/bpc-157 TB-500: https://www.bodyhackguide.co/compound/tb-500 GHK-Cu: https://www.bodyhackguide.co/compound/ghk-cu KPV: https://www.bodyhackguide.co/compound/kpv ## 11 Frequently Asked Questions the Wolverine Stack is a community nickname for BPC-157 combined with TB-500, a pairing no controlled human study has tested. GLOW is BPC-157, TB-500 and GHK-Cu, and KLOW is those three plus KPV. the Wolverine Stack bench sets each peptide's record beside the pair's and gives no amount, schedule or route for any of them. the Wolverine Stack covers 4 compounds: BPC-157, TB-500, GHK-Cu, KPV. ## Related Stacks 01 research bench Peptides for Hair Growth GHK-Cu, AHK-Cu, PTD-DBM, thymulin and follistatin-344, measured against minoxidil 6 compounds human data on 4 of 6 https://www.bodyhackguide.co/stack/hair-growth-peptides 02 research bench Peptides for Skin GHK-Cu, palmitoyl pentapeptide-4, acetyl hexapeptide-8 and Snap-8, next to the GLOW and KLOW blends 6 compounds human data on 4 of 6 https://www.bodyhackguide.co/stack/skin-peptides 03 research bench CJC-1295 + Ipamorelin GH Secretagogue Bench CJC-1295 and ipamorelin beside sermorelin, tesamorelin and MK-677, one receptor route at a time 6 compounds human data on 4 of 6 https://www.bodyhackguide.co/stack/gh-secretagogue-peptides ### Want a personalized stack? The Stack Builder matches you to the right protocol based on your goals, experience level, and medication sensitivities. Back to all stacks: https://www.bodyhackguide.co/stack Was this page helpful? BodyHackGuide (https://www.bodyhackguide.co/) Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. - Terms: https://www.bodyhackguide.co/terms - Privacy: https://www.bodyhackguide.co/privacy ## Structured data ```json [ { "@context": "https://schema.org", "@type": "WebPage", "name": "Wolverine Stack: research bench", "description": "the Wolverine Stack is a community nickname for BPC-157 combined with TB-500, a pairing no controlled human study has tested. GLOW is BPC-157, TB-500 and GHK-Cu, and KLOW is those three plus KPV. the Wolverine Stack bench sets each peptide's record beside the pair's and gives no amount, schedule or route for any of them.", "url": "https://www.bodyhackguide.co/stack/wolverine-stack", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the Wolverine Stack?", "acceptedAnswer": { "@type": "Answer", "text": "the Wolverine Stack is a community nickname for BPC-157 combined with TB-500, a pairing no controlled human study has tested. GLOW is BPC-157, TB-500 and GHK-Cu, and KLOW is those three plus KPV. the Wolverine Stack bench sets each peptide's record beside the pair's and gives no amount, schedule or route for any of them. the Wolverine Stack covers 4 compounds: BPC-157, TB-500, GHK-Cu, KPV." } }, { "@type": "Question", "name": "Is there human data behind the Wolverine Stack?", "acceptedAnswer": { "@type": "Answer", "text": "human data: no controlled human study of BPC-157 with TB-500; seven patients in two uncontrolled reports got BPC-157 with a thymosin beta-4 product, three of them as TB-500 alongside ARA-290, dexamethasone and bupivacaine; for BPC-157, three uncontrolled reports in 30 people, 4 of whom also got thymosin beta-4, and two randomized enema studies known only as meeting abstracts; none for TB-500 on its own; small topical trials for GHK-Cu; none for KPV. BPC-157 with TB-500: one controlled study, 32 rats with repaired Achilles tendons, in which the pair did no better than either peptide alone at four weeks, and two uncontrolled human reports covering seven patients. BPC-157: mostly rat work, with 174 of 228 PubMed records listing Predrag Sikiric of Zagreb as an author. BPC-157 in people: three uncontrolled reports that a 2026 systematic review rated very low certainty, and two randomized enema studies known only as meeting abstracts, the ulcerative colitis one judged inadequate by FDA. TB-500: no human data on its own in FDA's May 2026 review, a 2024 cell study in which TB-500 did no better than vehicle on fibroblast scratch wounds, and one 2026 rat tendon study. the published human trials of thymosin beta-4 used the full-length peptide, as eye drops, on skin ulcers and in one intravenous safety study. GHK-Cu: three topical wound and skin-resurfacing trials, one positive and two that failed on objective measures, and no published study with BPC-157, TB-500 or KPV. KPV: cell and mouse work, with no human exposure data by any route. FDA's adverse event file holds one report for a research-labeled BPC-157 and TB-500 product: skin and gum darkening after a week of use that returned on rechallenge. FDA judged the skin and gum darkening likely due to the BPC-157 and TB-500 product but could not assign it to either peptide." } }, { "@type": "Question", "name": "Why does the Wolverine Stack not list doses?", "acceptedAnswer": { "@type": "Answer", "text": "the research compounds on the Wolverine Stack are sold for laboratory research, not as supplements, so the bench sets out roles, evidence, overlap and conflicts for them, never amounts or schedules." } }, { "@type": "Question", "name": "What conflicts with the Wolverine Stack?", "acceptedAnswer": { "@type": "Answer", "text": "tested sport: WADA's 2026 list prohibits BPC-157 under S0 and thymosin beta-4 and its derivatives, TB-500 by name, under S2.3, at all times. WADA does not name KPV or GHK-Cu, but its S0 class prohibits at all times any substance with no current approval for human therapeutic use; whether S0 covers either one is a reading of that wording, not a WADA listing. cancer history: BPC-157 and the actin motif of thymosin beta-4 both drive new vessel growth in lab work, FDA found no carcinogenicity study of BPC-157 or TB-500, and FDA calls the human safety risks of TB-500 unknown. blood thinners and liver: FDA's summary of 28-day BPC-157 injection studies reports a shortened clotting test (aPTT) in rats, a prolonged one in dogs and raised ALT, a liver enzyme, and no study has tested BPC-157 in people taking anticoagulants. Wilson disease or another copper disorder with GLOW or KLOW: GHK-Cu supplies copper, zinc salts treat Wilson disease by competing with copper for absorption, and nobody has tested GHK-Cu in a copper disorder. pregnancy: FDA found no reproductive study of TB-500 or KPV, and for BPC-157 one rat study found no birth defects without a full reproductive program. overlapping products: the BPC-157 + TB-500 vial names both peptides, GLOW and KLOW carry both by market name, and neither the combined listing nor the KLOW listing states how much of each peptide a vial holds. immune reactions: FDA lists a possible immune response as a risk of compounded BPC-157, TB-500 and injectable GHK-Cu, citing aggregation or peptide impurities." } }, { "@type": "Question", "name": "Does BHG Labs sell these?", "acceptedAnswer": { "@type": "Answer", "text": "BHG Labs lists BPC-157 + TB-500 10mg; KLOW 80mg; GHK-Cu 50mg; KPV 10mg; and BPC-157 500mcg, 60 Dry-Fill Units for research use only. BHG Labs posts certificates for some of its products on its own certificates page (bhglabs.co/coa). BHG Labs has no GLOW listing and names TB-500 only on the BPC-157 + TB-500 vial." } }, { "@type": "Question", "name": "Who is the Wolverine Stack for?", "acceptedAnswer": { "@type": "Answer", "text": "people who searched for the Wolverine Stack, or for BPC-157 with TB-500, and want each peptide's record and the pair's before reading about GLOW or KLOW" } } ] }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co" }, { "@type": "ListItem", "position": 2, "name": "Stacks", "item": "https://www.bodyhackguide.co/stack" }, { "@type": "ListItem", "position": 3, "name": "Wolverine Stack", "item": "https://www.bodyhackguide.co/stack/wolverine-stack" } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```